

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Atar Dan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiarrhythmic drug development (2010-2011) - Sanofi Aventis : Antiarrhythmic drugs (2010-2011) - Merck Sharp & Dohme : Antiarrhythmic drugs (2010-2011) - Sequel Pharmaceuticals : Antiarrhythmic treatment in Atrial Fibrillation (2010) - Bayer : anticoagulants (2010-2011) - Boehringer-Ingelheim : Anticoagulants (2010-2011) - BMS/Pfizer : anticoagulants (2010-2011) - Pfizer : Cholesterol lowering (2010-2011) - Novartis : neurohumoral inhibition / blood pressure lowering (2010-2011) - Astra Zeneca : Platelet inhibition (2010-2011) - BMS : Prevention of Reperfusion Injury in STEMI (2010-2011) - Kai Pharmaceuticals : Prevention of Reperfusion Injury in STEMI (2010) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : anti-anginal medication (2010) - Population Research Institute, McMaster, Hamilton, Canada : Antiarrhythmic Therapy (2010) - TIMI group : anticoagulants (2010) - Duke Research Unit : Heart Failure Therapy (2010) - Servier : anti-anginal medication (2011) - Population Research Institute, McMaster, Hamilton, Canada : Antiarrhythmic Therapy (2011) - TIMI group : anticoagulants (2011) - Duke Research Unit : Heart Failure Therapy (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - EU-FP-7 grant / Trophos, Marseille : Prevention of Reperfusion Injury in STEMI (Leader of Clinical Research Consortium) (2010)

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Atar Dan	<ul style="list-style-type: none"> - EU-FP-7 grant / Trophos, Marseille : Prevention of Reperfusion Injury in STEMI (Leader of Clinical Research Consortium) (2011) E - Research funding (personal). <ul style="list-style-type: none"> - Pronova Bioscience : Omega-3 and Platelet Function (2010)
Badano Luigi Paolo	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Edwards Lifesciences : Clinical Event Committee member (2011) - Sorin Group : Consultancy (2011) - Malesci : Hypertension, hypercholesterolemia (2010) - Medtronic : Medical devices (2010) - GE Healthcare : Medical devices (2010) - GE Healthcare : Ultrasound (2011) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Actelion : Pulmonary hypertension (2010) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - GE Healthcare : medical devices (2010) E - Research funding (personal). <ul style="list-style-type: none"> - GE Healthcare : Ultrasound (2011)
Blomstrom-Lundqvist Carina	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Sanofi Aventis : AF (2011) - Medtronic : Pacemaker (2010) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Atricure : AF ablation (2010) - Biotronik : Arrhythmia (2011) - Medtronic : ICD, AF (2011) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Medtronic : AF (2011) - Atricure : AF (2011) - Biotronik : Arrhythmias (2011)

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Borger Michael A	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Edwards Lifesciences : heart valve therapy (2010-2011)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - St Jude Medical : heart valve therapy (2010) - St Jude Medical : heart valve therapy (2011)</p> <p>C - Receipt of royalties for intellectual property. - Medtronic : heart valve therapy (2010) - Medtronic : heart valve therapy (2011)</p>
Di Mario Carlo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Biomatrix stent (2010-2011) - Abbott Vascular : Xience stent (2010-2011)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Ikaria : Cardiac remodelling (2010) - Daiichi Sankyo, Eli-Lilly : Prasugrel (2010) - Medtronic : Resolute (2010) - Ikaria : Cardiac remodelling (2011) - Daiichi Sankyo, Eli-Lilly : Prasugrel (2011) - Medtronic : Resolute (2011)</p> <p>C - Receipt of royalties for intellectual property. - St Jude Medical : Optical coherence tomography (2010) - St Jude Medical : Optical coherence tomography (2011)</p> <p>D - Research funding (departmental or institutional). - Medicines Company : Bivalirudine (2010) - Medicines Company : Bivalirudine (2011)</p>
Dickstein Kenneth	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Adjudication Committee (2010) - Boston Scientific : CRT (2011) - Medtronic : CRT (2011)</p>

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Dickstein Kenneth	<ul style="list-style-type: none"> - Sorin Group : CRT (2011) - Biotronik : CRT (2011) - General Electric : DSMC (2010) - Cardiokine : DSMC/BALANCE (2010) - Boston Scientific : Honoraria (2010) - Medtronic : Honoraria (2010) - Sanofi Aventis : Steering Committee (2010) - Johnson & Johnson : Steering Committee/ASCEND (2010) - Novartis : Steering Committee/ATMOSPHERE (2010) - Biotronik : Steering Committee/ECHO-CRT (2010) - Vifor International : Steering COmmittee/FAIR-HF (2010) - Servier : Steering Committee/SHIFT (2010)
Ducrocq Gregory	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet agents (2010-2011) - Eli Lilly : Antiplatelet agents (2010-2011) - Medtronic : Stents (2010-2011)
Fernandez-Aviles Francisco	None
Gershlick Anthony H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott Vascular : ABSORB stents (2010) - Medtronic : Advisory board (2010) - Astra Zeneca : anti-platelet agent (2011) - Daiichi Sankyo : anti-platelet agent (2011) - Sanofi Aventis : anti-platelet anti thrombins (2010) - Astra Zeneca : anti-platelet therapy (2010) - Medicines Company : anti-thrombin (2011)

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Gershlick Anthony H	<ul style="list-style-type: none"> - Cardiovascular Research Foundation : Associate board memeber (2011) - Medicines Company : Bivalirudin (2010) - Lilly : Prasugrel (2010) - Boston Scientific : stent interventional products (2011) - Medtronic : stent interventional products (2011) - Abbott Vascular : stent interventional products (2011) - Boston Scientific : STENTS (2010) - Astra Zeneca : Ticagrelor (2010) - Boehringer-Ingelheim : TNK (2010) - Boehringer-Ingelheim : trial TNK (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : STENTS (2010)</p> <p>D - Research funding (departmental or institutional). - Cordis : stents (2010)</p> <p>E - Research funding (personal). - Abbott Vascular : STENTS (2010)</p>
Giannuzzi Pantaleo	None
Halvorsen Sigrun	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme Corp in conjunctin with Duke Clinical Research Center : antidiabetic drugs (2010-2011) - Bristol Myers Squibb : Antithrombotic treatment (2010-2011) - Astra Zeneca : Anti-thrombotic treatment (2011) - Boehringer-Ingelheim : Anti-thrombotic treatment (2011) - Nycomed : Anti-thrombotic treatment (2010-2011) - Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : Anti-thrombotic treatmnet (2010-2011) - Astra Zeneca : treatment of acute coronary syndrome (2010) - Sanofi Aventis : Treatment of Afib (2010-2011)

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Huber Kurt	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : atorvastatin (2010) - Pfizer : atorvastatin, edoxaban (2011) - Medicines Company : bivalirudin; cangrelor (2010-2011) - BRAHMS GmbH : copeptin assay (2010-2011) - Boehringer-Ingelheim : dabigatran (2010-2011) - Boston Scientific : none (2010) - Biotronik : none (2010) - Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : prasugrel; abciximab (2010-2011) - Bayer : rivaroxaban (2010-2011) - Astra Zeneca : ticagrelor; rosuvastatin (2010-2011)
James Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : coagulation inhibition (2011) - Astra Zeneca : Platelet inhibition (2011) - Eli Lilly : platelet inhibition (2011) - Eli Lilly : Prasugrel Anti thrombotic therapy (2010) - Abbott : Stents (2010) - Boston Scientific : Stents (2010) - Astra Zeneca : Ticagrelor Anti thrombotic therapy (2010) - Merck Sharp & Dohme : Vorapaxar Anti thrombotic therapy (2010) - Astra Zeneca : platelet inhibition (2011) - Eli Lilly : platelet inhibition (2011) - Medtronic : thrombus asp catheter (2011) - Terumo Inc : thrombus asp catheter (2011) - Vascular solutions : thrombus asp catheter (2011)

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
James Stefan	D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Medtronic : Thrombus aspiration (2010) - Terumo Inc : Thrombus aspiration (2010) - Vascular solutions : Thrombus aspiration (2010) - Astra Zeneca : Ticagrelor (2010)
Juni Peter	None
Kastrati Adnan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Medicines Company : Anticoagulant drugs (2011) - Merck Sharp & Dohme : Anticoagulant drugs (2011) - Daiichi Sankyo : Antiplatelet drugs (2011) - Abbott : DES (2010) - Biosensors : Stents (2011) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet (2010) - Lilly : Antiplatelet (2010) - Biosensors : DES (2010) - Biotronik : DES (2010) - Cordis : DES (2010) - B.Braun : Stents (2011) - Abbott Vascular : Stents (2011)
Knuuti Juhani	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Lantheus Inc : Imaging tracers (2010) - Lantheus Inc : Perfusion imaging tracer development (2011) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Bayer : Development of imaging agents (2010) - Novartis : Development of imaging agents (2010) - GE Healthcare : Development of imaging agents (2010)

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Knuuti Juhani	<ul style="list-style-type: none"> - Lantheus Inc : Development of imaging agents (2010) - Roche Pharma : Drugs for brain diseases (2010) - Astra Zeneca : Neurology (2011) - GE Healthcare : Neurology and molecular imaging (2011)
Lenzen Mattie	None
Mahaffey Kenneth W	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Amgen : Cardiovascular (2011) - Bayer : Cardiovascular (2011) - BMS : Cardiovascular (2011) - Boehringer-Ingelheim : Cardiovascular (2011) - Daiichi Sankyo : Cardiovascular (2011) - Eli Lilly : Cardiovascular (2011) - Medtronic : Cardiovascular (2011) - Pfizer : Cardiovascular (2011) - St Jude Medical : Cardiovascular (2011) - Biotronik : Cardiovascular (2011) - Sanofi Aventis : Cardiovascular (2011) - Johnson & Johnson : Cardiovascular (2011) - Genentech : Cardiovascular (2011) - Gilead : Cardiovascular (2011) - Elsevier : Cardiovascular (2011) - Adolor : Cardiovascular (2011) - Forest : Cardiovascular (2011) - Haemonetics : Cardiovascular (2011) - Merck Pharm : Cardiovascular (2011)

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Mahaffey Kenneth W	<ul style="list-style-type: none"> - Ortho-McNeill : Cardiovascular (2011) - Polymedix : Cardiovascular (2011) - South East Area Health Education Center (SEAHEC) : Cardiovascular (2011) - Springer Publishing : Cardiovascular (2011) - Sun Pharma : Cardiovascular (2011) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Amgen : Cardiovascular (2011) - Astra Zeneca : Cardiovascular (2011) - Bayer : Cardiovascular (2011) - Boehringer-Ingelheim : Cardiovascular (2011) - Daiichi Sankyo : Cardiovascular (2011) - Edwards Lifesciences : Cardiovascular (2011) - Eli Lilly : Cardiovascular (2011) - Medtronic : Cardiovascular (2011) - Novartis : Cardiovascular (2011) - Baxter : Cardiovascular (2011) - GlaxoSmithKline : Cardiovascular (2011) - Johnson & Johnson : Cardiovascular (2011) - Ikaria : Cardiovascular (2011) - Abbott Vascular : Cardiovascular (2011) - Medicines Company : Cardiovascular (2011) - Portola Pharmaceuticals : Cardiovascular (2011) - Regado Biosciences : Cardiovascular (2011) - Bristol Myers Squibb : Cardiovascular (2011) - Amylin : Cardiovascular (2011)

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Mahaffey Kenneth W	<ul style="list-style-type: none"> - Merck Sharp & Dohme : Cardiovascular (2011) - Cordis : Cardiovascular (2011) - Guidant : Cardiovascular (2011) - Luitpold : Cardiovascular (2011) - Pozen : Cardiovascular (2011) - Roche Diagnostics : Cardiovascular (2011) - Various : Cardiovascular (2011)
Steg Philippe Gabriel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : antianginal agents (2010-2011) - Bayer : anticoagulants (2010-2011) - Astellas : Anticoagulants (2010-2011) - Eisai : antiplatelet agent (2010) - Astra Zeneca : antiplatelet agents (2010-2011) - Daiichi Sankyo : antiplatelet agents (2010-2011) - Boehringer-Ingelheim : antithrombotics (2010-2011) - Sanofi Aventis : antithrombotics (2010-2011) - GlaxoSmithKline : antithrombotics (2010-2011) - Medicines Company : antithrombotics (2010-2011) - Bristol Myers Squibb : antithrombotics (2010-2011) - Merck Sharp & Dohme : Antithrombotics (2010) - Lilly : antithrombotics and lipid lowering drugs (2011) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : Contrast agents (2011) - Vivus : Drugs for obesity (2011) - Pfizer : heart failure (2010) - Amarin : Lipid compounds (2011)

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Steg Philippe Gabriel	<ul style="list-style-type: none"> - Amgen : Lipid lowering treatment (2010) - Medtronic : stents (2010-2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : Registry on coronary artery disease (2010) - Sanofi Aventis : Clinical trial on lipids (2011) - Servier : Registry on coronary artery disease (2011)
Valgimigli Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medicines Company : bivalirudin (2010-2011) - Terumo Inc : Interventional cardiology (2010-2011) - Abbott Laboratories : ngal (2010-2011) - Accumetrics : Platlet Function Assay (2010-2011) - Roche Pharma : PPAR alpha/gamma (2010-2011) - Medtronic : stent (2010-2011) - Abbott Vascular : stent (2010-2011) - Cordis : stent (2010-2011) - CID : stent (2010-2011) - Astra Zeneca : ticagrelor (2010-2011) - Chiesi Pharma : tirofiban (2010-2011) - Iroko Cardio : Tirofiban (2010-2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott Laboratories : ngal (2010) - Abbott Laboratories : ngal (2011)
van't Hof Arnoud W J	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Advisory Board (2010-2011) - Daiichi Sankyo : Advisory Board (2010-2011) - Lilly : Advisory Board (2010-2011)

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
van't Hof Arnoud W J	<ul style="list-style-type: none"> - Medicines Company : Advisory Board (2010-2011) - Iroko Cardio : Speaker Fee (2010-2011) - Merck Sharp & Dohme : Speaker fees (2010-2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Educational Grant (2010) - Pfizer : Educational Grant (2010) - Lilly : Educational Grant (2010) - Astra Zeneca : Educational Grant (2011) - Pfizer : Educational Grant (2011) - Lilly : Educational Grant (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Unrestricted Grant (2010) - Medtronic : Unrestricted Grant (2011) - Medicines Company : Unrestricted Grant (2011) - Merck Sharp & Dohme : Unrestricted Grant (2011)
Widimsky Petr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Antiischemic agents (2010) - Astra Zeneca : Antithrombotic agents (2010-2011) - Bayer : Antithrombotic agents (2010-2011) - Boehringer-Ingelheim : Antithrombotic agents (2010-2011) - Daiichi Sankyo : Antithrombotic agents (2010-2011) - Eli Lilly : Antithrombotic agents (2010-2011) - Duke University : Antithrombotic agents (2010-2011) - Medicines Company : Antithrombotic agents (2010) - Abbott : Stents (2010-2011) - Boston Scientific : Stents (2010-2011)

Guidelines on AMI-STEMI (TF11) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Widimsky Petr	- Medtronic : Stents (2010-2011)
Zahger Doron	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : apixabana (2011) - Boehringer-Ingelheim : dabigatran (2011) - Sanofi Aventis : Dronedarone (2010) - Pfizer : lipitor (2010) - Eli Lilly : prasugrel (2010) - Bayer : Rivaroxaban (2011) - ,astra zeneca, boheringer, menarini : Ticagrelor (2010-2011)

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

Guidelines on AMI-STEMI (TF11) - Document Reviewers

Expert	Type of Relationship with Industry
Astin Felicity	None
Astrom-Olsson Karin	None
Budaj Andrzej	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban (2011) - Boehringer-Ingelheim : dabigatran (2011) - GlaxoSmithKline : darapladib (2011) - Sanofi Aventis : dronedarone (2011) - Sanofi Aventis : glargine (2011) - Duke Institute : prasugrel (2011) - Astra Zeneca : ticagrelor (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban (2011) - Boehringer-Ingelheim : dabigatran (2011) - GlaxoSmithKline : darapladib (2011) - Sanofi Aventis : dronedarone (2011) - Astra Zeneca : ticagrelor (2011)
Clemmensen Peter Michael	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anti-Patelets (2011) - Eli Lilly : Anti-platelets (2011) - Evolva : Anti-platelets (2011) - Bayer Healthcare : Antithrombotics (2011) - Medicines Company : Antithrombotics (2011) - Boehringer-Ingelheim : Diabetes and Antithrombotics (2011) - Medtronic : Ischemia Monitoring (2011) - Servier : Ischemic Heart Disease (2011) - Pfizer : Lipids (2011)

Guidelines on AMI-STEMI (TF11) - Document Reviewers

Expert	Type of Relationship with Industry
Clemmensen Peter Michael	<ul style="list-style-type: none"> - Merck Sharp & Dohme : Lipids (2011) - Astra Zeneca : Lipids and ACS (2011) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Daiichi Sankyo : Antiplatelets (2011) - Eli Lilly : Antiplatelets (2011) - Medicines Company : Antithrombotics (2011) - F. Hoffman La Roche Ltd : Diabetes (2011) - Servier : Ischemic Heart Disease (2011)
Collet Jean-Philippe	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Bristol Myers Squibb : advisory board and speaker fees (2011) - Astra Zeneca : advisory board fees (2011) - Medicines Company : consultancy (2011) - Eli Lilly : speaker fees (2011) - Sanofi Aventis : speaker fees (2011) - Abbott Vascular : speaker fees (2011) - Daiichi Sankyo : speaker fees (2011) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Société Française de Cardiologie : platelet function testing (2011) E - Research funding (personal). <ul style="list-style-type: none"> - Accumetrics : functional platelet testing (2011) - Nanosphere : genetic testing (2011) - Eli Lilly : prasugrel (2011) - Abbott Vascular : stents (2011)
Fox Keith	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Eli Lilly : ACS (2011) - Bayer : Atrial fibrillation (2011) - Duke University : Atrial Fibrillation and anti-thrombotic therapy (2011)

Guidelines on AMI-STEMI (TF11) - Document Reviewers

Expert	Type of Relationship with Industry
Fox Keith	<ul style="list-style-type: none"> - TIMI group : Studies of thrombosis in coronary disease (2011) - Boehringer-Ingelheim : Thrombosis, Atrial fibrillation (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Lilly : anti-thrombotic therapy (2011) - Bayer : atrial fibrillation (2011)
Fuat Ahmet	None
Gustiene Olivija	None
Hamm Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : drugs (2011) - Pfizer : drugs (2011) - Sanofi Aventis : drugs (2011) - GlaxoSmithKline : drugs (2011) - Menarini : drugs (2011) - Berlin Chemie AG : drugs (2011) - Heart.org : drugs (2011) - Medicines Company : drugs (2011) - Boehringer Ingelheim - Ingelheim; Daiichi-Sankyo/Eli Lilly; Nycomed Pharma : drugs (2011) - Takeda Pharmaceuticals : drugs (2011) - Astra Zeneca, Bayer AG, Boehringer-Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi-Aventis, Servier : drugs (2011) - Merck Sharp & Dohme : drugs (2011) - BRAHMS GmbH : markers (2011) - Siemens Healthcare : MRI (2011) - Boston Scientific : PCI (2011) - Cordis and Medtronic : PCI (2011)

Guidelines on AMI-STEMI (TF11) - Document Reviewers

Expert	Type of Relationship with Industry
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Pradaxa (2011) - Bayer : Rivaroxiban (2011) - Astra Zeneca : Ticagrelor (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Eli Lilly : Effient (2011)
Kala Petr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Eli Lilly : ACS (2011) - St Jude Medical : Coronary imaging (2011) - Boston Scientific : Interventional Cardiology (2011) - Johnson & Johnson : Interventional Cardiology (2011) - Abbott Vascular : Interventional Cardiology (2011) - B.Braun : Interventional Cardiology (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : ACS trial (2011) - Ablynx : ACS trial (2011) - Boston Scientific : Interventional Cardiology (2011)
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boston Scientific : Heart Failure (2011) - Bayer Healthcare : Xarelto (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Coversyl (2011) - Astra Zeneca : Crestor (2011)
Maggioni Aldo Pietro	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : Aliskiren (2011) - BMS : Apixaban (2011) - Actelion : Bosentan (2011)

Guidelines on AMI-STEMI (TF11) - Document Reviewers

Expert	Type of Relationship with Industry
Maggioni Aldo Pietro	<ul style="list-style-type: none"> - Amgen : Derbapoietin (2011) - Oxford University : Exanatide (2011) - Servier : Ivabradine (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - GlaxoSmithKline : Acute coronary syndromes (2011) - Boehringer-Ingelheim : Atrial fibrillation (2011) - Sanofi Aventis : Diabetes (2011)
Merkely Bela	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Krka : ACS (2011) - Sanofi Aventis : Atrial Fibrillation (2011) - Boston Scientific : CRT (2011) - Medtronic : CRT course (2011) - St Jude Medical : CRT/ICD (2011) - Servier : Heart Failure (2011) - Biotronik : ICD/CRT (2011) - Abbott : STEMI (2011) - GE Healthcare : STEMI networking (2011) - Duke Institute : TrilogY Study (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boston Scientific : CRT (2011) - Biotronik : ICD/CRT Heart Failure (2011) - University of Leuven : NOMI trial (2011) - GE Healthcare : STEMI (2011) - Duke Research Unit : TrilogY Study (2011)
Neumann Franz Josef	

Guidelines on AMI-STEMI (TF11) - Document Reviewers

Expert	Type of Relationship with Industry
Neumann Franz Josef	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet therapy (2011) - Daiichi Sankyo : Antiplatelet therapy (2011) - Lilly : Antiplatelet therapy (2011) - Medicines Company : Antithrombotic therapy (2011) - Boston Scientific : Interventional Cardiology (2011) - Medtronic : Interventional Cardiology (2011) - Biotronik : Interventional Cardiology (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Lilly : Antiplatelet therapy (2011) - Medicines Company : Antithrombotic therapy (2011) - Roche Pharma : Diabetes (2011) - Boston Scientific : Interventional Cardiology (2011) - Medtronic : Interventional Cardiology (2011) - Cordis : Interventional Cardiology (2011) - Braun : Interventional Cardiology (2011)
Piepoli Massimo Francesco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-dyslipidemic therapy (2011) - Abbott Vascular : Anti-dyslipidemic therapy (2011) - Bayer : Anti-hypertensive therapy (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Pfizer : Secondary prevention (2011)
Van de Werf Frans	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : antithrombotic agents (2011) - Boehringer-Ingelheim : antithrombotic agents (2011) - Merck Sharp & Dohme : antithrombotic agents (2011)

Guidelines on AMI-STEMI (TF11) - Document Reviewers

Expert	Type of Relationship with Industry
Van de Werf Frans	D - Research funding (departmental or institutional). - Boehringer-Ingelheim : tenecteplase (2011) - Merck Sharp & Dohme : vorapaxar (2011)
Verheugt Freek	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : anticoagulants (2011)
Wallentin Lars	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS : Atrial fibrillation (2011) - Boehringer-Ingelheim : Atrial fibrillation (2011) - Pfizer : Atrial fibrillation (2011) - Roche Diagnostics : Biomarkers (2011) - GlaxoSmithKline : Coronary artery disease (2011) - Astra Zeneca : Myocardial infarction (2011) - Evolva : Myocardial infarction (2011) - Athera : Myocardial infarction (2011) - Regado Biosciences : Myocardial infarction (2011) - Merck Sharp & Dohme : Myocardial infarction (2011) C - Receipt of royalties for intellectual property. - Roche Diagnostics : Myocardial infarction (2011) D - Research funding (departmental or institutional). - BMS : Atrial fibrillation (2011) - Boehringer-Ingelheim : Atrial fibrillation (2011) - GlaxoSmithKline : Coronary artery disease (2011) - Astra Zeneca : Myocardial infarction (2011) - Merck Sharp & Dohme : Myocardial infarction (2011)

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan for PAH treatment in congenital heart disease (2010-2011) - AGA : Devices for catheter treatment of congenital heart defects (2010) - Edwards Lifesciences : transcatheter valve implantation (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : transcatheter valve implantation (2010) - Actelion : Bosentan for PAH treatment in congenital heart disease (2011) - Edwards Lifesciences : transcatheter valve implantation (2011)
Bax Jeroen	<ul style="list-style-type: none"> - Heart.org : Education (2010) - Astra Zeneca : Farma (2010) - Servier : Farma (2010) - Philips : Imaging (2010) - GE Healthcare : Imaging (2010) - Lantheus Inc : Imaging (2010) - Boston Scientific : Pacing (2010) - Medtronic : Pacing (2010) - St Jude Medical : Pacing (2010) - Biotronik : Pacing (2010) - Impulse Dynamics : Pacing (2010) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : Farma (2010) - Edwards Lifesciences : Heart Valves (2010) - GE Healthcare : Imaging (2010) - Lantheus Inc : Imaging (2010) - Boston Scientific : Pacing (2010) - Medtronic : Pacing (2010) - St Jude Medical : Pacing (2010) - Biotronik : Pacing (2010) - Servier : Farma (2011) - Edwards Lifesciences : Heart Valves (2011) - GE Healthcare : Imaging (2011) - Lantheus Inc : Imaging (2011) - Boston Scientific : Pacing (2011)

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Bax Jeroen	<ul style="list-style-type: none"> - Medtronic : Pacing (2011) - St Jude Medical : Pacing (2011) - Biotronik : Pacing (2011)
Ceconi Claudio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Pharmaceutical (2010-2011)
Deaton M Christi	<ul style="list-style-type: none"> - St Jude Medical : Cath lab - speaker X 1 (2010) - Daiichi Sankyo : consultant for patient adherence 2009-10 (2010) - Eli Lilly : consultant for patient adherence 2009-10 (2010) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Novo-Nordisk : medicines for diabetes (2010) - Novo-Nordisk : patients with heart failure and diabetes (2011)
Fagard Robert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Honorarium for manuscript (2011) - Servier : Honorarium for manuscript in Medicographia (2010)
Funck-Brentano Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis CH : Adjudication Committee on an immunosuppressant (2011) - Lundbeck : Cardiac safety of an antidepressant (2011) - Pierre-Fabre : Cardiac Safety of non-cardiovascular products (2010-2011) - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2010-2011) - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - MMV (CH) : Cardiac Safety of an antimalarial drug (2010-2011) - Santhera (CH) : Cardiac Safety of an antimalarial drug (2010-2011) - Sigma Tau : Cardiac Safety of an antimalarial drug (2010-2011) - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety (2010-2011) - CEPHALON : DSMB in an oncology phase IIb trial (2010-2011) - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel (2010-2011) - Intracellular Therapies USA : Psychotropic drug development (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel (2010)
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Enoxaparin (2010) - Boehringer-Ingelheim : Pradaxa (2011)

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Hasdai David	<ul style="list-style-type: none"> - Bayer : Rivaroxiban (2011) - Astra Zeneca : Ticagrelor (2011) - Eli Lilly : Effient (2011)
Hoes Arno	<ul style="list-style-type: none"> - Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips - Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Bayer Healthcare : unrestricted grant for diagnostic kits in suspected cardiovascular disease (2010) - Abbott Laboratories : unrestricted grant for diagnostic kits in suspected cardiovascular disease (2010) - Roche Pharma : unrestricted grant for diagnostic kits in suspected heart failure and acute coronary syndrome (2010) - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2011)
Kirchhof Paulus	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - BMS : cardiovascular (2011) - Boehringer-Ingelheim : cardiovascular (2011) - Daiichi Sankyo : cardiovascular (2011) - Medtronic : cardiovascular (2011) - St Jude Medical : cardiovascular (2011) - Sanofi Aventis : cardiovascular (2011) - Meda pharma : cardiovascular (2011) - Merck Sharp & Dohme : cardiovascular (2011) - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2011) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - St Jude Medical : cardiovascular (2011) - Sanofi Aventis : cardiovascular (2011) - Meda pharma : cardiovascular (2011)
Knuuti Juhani	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Lantheus Inc : Imaging tracers (2010) - Lantheus Inc : Perfusion imaging tracer development (2011)

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Knuuti Juhani	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer : Development of imaging agents (2010) - Novartis : Development of imaging agents (2010) - GE Healthcare : Development of imaging agents (2010) - Lantheus Inc : Development of imaging agents (2010) - Roche Pharma : Drugs for brain diseases (2010) - Astra Zeneca : Neurology (2011) - GE Healthcare : Neurology and molecular imaging (2011)
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Antiarrhythmic agents (2010) - Merck Sharp & Dohme : Antiarrhythmic agents (2011) - Astra Zeneca : Antiplatelet agents (2010-2011) - Bristol Myers Squibb : Antiplatelet agents (2010) - Regado Biosciences : Antithrombotic agents (2010-2011) - Abbott : coronary stents (2010) - Abbott Vascular : Coronary stents (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Antistaphylococcic vaccine (2010) - Merck Sharp & Dohme : Antistaphylococcic vaccine (2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Cardiac valves (2010) - Medtronic : Cardiac valves (2010) - St Jude Medical : Cardiac valves (2010) - Siemens Healthcare : Imaging (2010) - Johnson & Johnson : Thoracoscopic devices (2010) - Edwards Lifesciences : Cardiac valves (2011) - Medtronic : Cardiac valves (2011) - St Jude Medical : Cardiac valves (2011) - Boston Scientific : Coronary stents (2011) - Siemens Healthcare : Medical imaging (2011) - Johnson & Johnson : Thoracoscopic devices (2011)

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
McDonagh Theresa	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Vifor International : Ferrinject (2010-2011)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabridine (2010) - Servier : Ivabridine (2011)</p> <p>D - Research funding (departmental or institutional). - Biotronik : CRT (2010)</p>
Popescu Bogdan Alexandru	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : Imaging (2010-2011)</p>
Reiner Zeljko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : anticoagulants (2011) - Bayer Healthcare : anticoagulants (2010) - Abbott : antilipemics (2010) - Astra Zeneca : antilipemics (2010-2011) - Pfizer : antilipemics (2010-2011) - Sanofi Aventis : antilipemics (2011) - Abbott Laboratories : antilipemics (2011) - Merck Sharp & Dohme : antilipemics (2010) - Merck Sharp & Dohme : antilipemics (2011)</p>
Sechtem Udo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2010-2011) - Daiichi Sankyo : Antiplatelet therapy (2010) - Novartis : Drugs (2010-2011) - Pfizer : Drugs (2011) - Siemens Healthcare : Imaging (2010) - General Electric : Imaging (2010)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Imaging devices (2010) - Johnson & Johnson : Stents (2010) - Novartis : Drugs (2011) - Johnson & Johnson : Stents (2011)</p>

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Sirnes Per Anton	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer : clinical studies atrial fibrillation investigator fee (ROCKET) (2010) - Merck Sharp & Dohme : investigator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2010) - GlaxoSmithKline : investigator fee, clinical study , SCAD (2010) - Sanofi Aventis : investigator fee, clinical study (PALLAS) (2010) - Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2010) - Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2010) - Boehringer-Ingelheim : investigator fee, clinical study, AF (RELY. RELYABLE) (2010) - Merck Sharp & Dohme : investigator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2011) - GlaxoSmithKline : investigator fee, clinical study , SCAD (2011) - Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2011) - Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2011)
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Aspirin, Rivaroxaban (2011) - Amgen : Darbopietin (2011) - Servier : Ivabradine, Phase II investigational products (2011) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Ivabradine, Phase II investigational products (2011) - TIMI group : Rivaroxaban (2011)
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulation (2010) - Sanofi Aventis : anticoagulation (2010) - Pfizer : anticoagulation, pulmonary hypertension (2010) - United Therapeutics : Pulmonary arterial hypertension (2011) - GSK : pulmonary arterial hypertension - ambrisentan (2011) - Actelion : pulmonary arterial hypertension - macisentan, selexipag (2011) - Lilly : pulmonary arterial hypertension - tadalafil (2011) - AOP : Pulmonary arterial hypertension - treprostinil (2011) - Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat (2011) - Actelion : pulmonary hypertension (2010) - Lilly : pulmonary hypertension (2010) - Bayer Healthcare : pulmonary hypertension, anticoagulation (2010) - Bristol Myers Squibb : thromboembolic disease - Apixaban (2011)

ESC Committee for Practice Guidelines 2010-2012

Expert	Type of Relationship with Industry
Torbicki Adam	<ul style="list-style-type: none"> - Bayer Healthcare : Pulmonary hypertension (2011) - Sanofi Aventis : Thromboembolic disease (2011)
Vahanian Alec	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott : valve disease (2011) - Valtech : valve disease (2011) - Medtronic Foundation : valve disease (2011) - saint Jude medical : valve disease (2011) - Edwards Life sciences : valve disease (2011) - Abbott : Valve prostheses (2010) - Boehringer-Ingelheim : Valve prostheses (2010) - Edwards Lifesciences : Valve prostheses (2010) - Medtronic : Valve prostheses (2010) - Valtech : Valve prostheses (2010) - Siemens Healthcare : Valve prostheses (2010)
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet drug (2010-2011) - Eli Lilly : Antiplatelet drug (2010-2011) - Abbott : Stent (2010-2011) - Biosensors : Stent (2010-2011) - Boston Scientific : Stent (2010-2011) - Medtronic : Stent (2010-2011) - Biotronik : Stent (2010-2011) - Cordis : Stent (2010-2011) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott : Stent (2010) - Biosensors : Stent (2010) - Medtronic : Stent (2010) - Cordis : Stent (2010) - St Jude Medical : OCT (2011) - Abbott : Stent (2011) - Biosensors : Stent (2011) - Medtronic : Stent (2011) - Biotronik : Stent (2011)

Expert	Type of Relationship with Industry
Windecker Stephan	- Cordis : Stent (2011)

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.